Epilepsy
9 videos · updated daily
46:48 Polaryx Therapeutics on Paediatric Lysosomal Disorders
Alex Yang, Chairman and CEO of Polaryx Therapeutics, a clinical-stage company developing therapies for rare paediatric lysosomal storage disorders, discusses on Progress, Potential, and Possibilities enhancing the cell's own clearance machinery.
32:38 Getting 15q13.3 Ready for Clinical Trials
Ingo Helbig, MD, of Children's Hospital of Philadelphia and the University of Pennsylvania describes seizures in 15q13.3 and what it takes to make the condition trial-ready, from natural history data to EEG biomarkers, for Reed's Reach for 15q13.3.
44:56 The KCNA2 Patient Registry and Trial Readiness
Dr. Jan Henji Driedger, child neurologist at Heidelberg University Hospital, discusses on The KCNA2 & Rare Epilepsy Podcast how the KCNA2 patient registry gathers natural-history data and helps prepare families for future clinical trials.
57:28 CAMP4’s SYNGAP1 ASCEND Phase 1/2 Trial: What You Need to Know
Yuri Maricich, MD, MBA, Chief Medical Officer of CAMP4 Therapeutics, explains the company's SYNGAP1 ASCEND Phase 1/2 trial and answers families' questions, for CURE SYNGAP1.
Walter Koroshetz on the State of Epilepsy Research
Former NINDS Director Dr. Walter Koroshetz discusses the state of epilepsy research, federal research funding, and how government, academia, industry and nonprofits do and don't collaborate, on CURE Epilepsy's Seizing Life podcast.
17:56 Praxis EMERALD Phase 3 Decentralized Trial
Kelly Del Real, Director of Patient Strategy at Praxis, presents the EMERALD study of relutrigine, a Phase 3 decentralized clinical trial in developmental and epileptic encephalopathies, to the STXBP1 Disorders community in January 2026.
49:04 TrustTSC Trial of Ganaxolone in TSC Seizures
Dr. Ian Miller of Marinus Pharmaceuticals and Dr. David Ritter of Cincinnati Children's Hospital describe the TrustTSC trial of investigational ganaxolone for TSC-associated seizures, which in April 2023 was enrolling in the US and Europe.
6:58 PRAIS Clinical Trial Update on Reluchagene (Part 15)
In Part 15 of SCN8A Awareness Day 2026, Julia Chase from PRAIS shares an update on the reluchagene clinical program.
7:01 Cenobamate Responses Across Focal Seizure Subtypes
William E. Rosenfeld, MD, of the Comprehensive Epilepsy Care Center for Children and Adults discusses a post-hoc analysis of the C021 trial of cenobamate (NCT02535091), assessing its efficacy across focal seizure subtypes in 240 patients.